Literature DB >> 26655325

CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women.

Carola R Röhrich1, Britt I Drögemöller1, Ogechi Ikediobi2, Lize van der Merwe3,4, Nelis Grobbelaar5, Galen E B Wright1, Nathaniel McGregor1,6, Louise Warnich1.   

Abstract

Long-term exposure to efavirenz (EFV) measured in hair samples may predict response to antiretroviral treatment (ART). Polymorphisms in CYP2B6 are known to alter EFV levels. The aim of this study was to assess the relationship between CYP2B6 genotype, EFV levels measured in hair, and virological outcomes on ART in a real-world setting. We measured EFV levels in hair from HIV-positive South African females who had been receiving EFV-based treatment for at least 3 months from the South African Black (SAB) (n = 81) and Cape Mixed Ancestry (CMA) (n = 53) populations. Common genetic variation in CYP2B6 was determined in 15 individuals from each population using bidirectional Sanger sequencing. Prioritized variants (n = 16) were subsequently genotyped in the entire patient cohort (n = 134). The predictive value of EFV levels in hair and selected variants in CYP2B6 on virological treatment outcomes was assessed. Previously described alleles (CYP2B6*2, CYP2B6*5, CYP2B6*6, CYP2B6*17, and CYP2B6*18), as well as two novel alleles (CYP2B6*31 and CYP2B6*32), were detected in this study. Compared to noncarriers, individuals homozygous for CYP2B6*6 had ∼109% increased EFV levels in hair (p = .016) and CYP2B6*18 heterozygotes demonstrated 82% higher EFV hair levels (p = .0006). This study confirmed that alleles affecting CYP2B6 metabolism and subsequent EFV exposure are present at significant frequencies in both the SAB and CMA populations. Furthermore, this study demonstrated that the use of hair samples for testing EFV concentrations may be a useful tool in determining long-term drug exposure in resource-limited countries.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26655325      PMCID: PMC4892230          DOI: 10.1089/AID.2015.0048

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  72 in total

1.  GeneSplicer: a new computational method for splice site prediction.

Authors:  M Pertea; X Lin; S L Salzberg
Journal:  Nucleic Acids Res       Date:  2001-03-01       Impact factor: 16.971

2.  AliBaba2: context specific identification of transcription factor binding sites.

Authors:  Niels Grabe
Journal:  In Silico Biol       Date:  2002

3.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

4.  Mfold web server for nucleic acid folding and hybridization prediction.

Authors:  Michael Zuker
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

5.  Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles.

Authors:  Thomas Lang; Kathrin Klein; Tanja Richter; Arne Zibat; Reinhold Kerb; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  J Pharmacol Exp Ther       Date:  2004-06-09       Impact factor: 4.030

6.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

7.  Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression.

Authors:  Vishal Lamba; Jatinder Lamba; Kazuto Yasuda; Stephen Strom; Julio Davila; Michael L Hancock; James D Fackenthal; Peter K Rogan; Barbara Ring; Steven A Wrighton; Erin G Schuetz
Journal:  J Pharmacol Exp Ther       Date:  2003-10-09       Impact factor: 4.030

8.  Human non-synonymous SNPs: server and survey.

Authors:  Vasily Ramensky; Peer Bork; Shamil Sunyaev
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

9.  Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Authors:  Chantal Csajka; Catia Marzolini; Karin Fattinger; Laurent A Décosterd; Jacques Fellay; Amalio Telenti; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacol Ther       Date:  2003-01       Impact factor: 6.875

Review 10.  Sex differences in pharmacokinetics and pharmacodynamics.

Authors:  Monica Gandhi; Francesca Aweeka; Ruth M Greenblatt; Terrence F Blaschke
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

View more
  12 in total

1.  A validated liquid chromatography/tandem mass spectrometry method for the analysis of efavirenz in 0.2 mg hair samples from human immunodeficiency virus infected patients.

Authors:  Jenna Johnston; Catherine Orrell; Peter Smith; Anton Joubert; Lubbe Wiesner
Journal:  Rapid Commun Mass Spectrom       Date:  2018-04-30       Impact factor: 2.419

Review 2.  Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.

Authors:  Andrea Calcagno; Jessica Cusato; Antonio D'Avolio; Stefano Bonora
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

Review 3.  Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.

Authors:  Pan-Fen Wang; Alicia Neiner; Evan D Kharasch
Journal:  Drug Metab Dispos       Date:  2019-07-19       Impact factor: 3.922

4.  Antiretroviral Concentration in Hair as a Measure for Antiretroviral Medication Adherence: A Systematic Review of Global Literature.

Authors:  Quan Zhang; Shan Qiao; Xueying Yang; Xiaoming Li
Journal:  AIDS Behav       Date:  2020-01

Review 5.  Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.

Authors:  Keneuoe Cecilia Nthontho; Andrew Khulekani Ndlovu; Kirthana Sharma; Ishmael Kasvosve; Daniel Louis Hertz; Giacomo Maria Paganotti
Journal:  Pharmgenomics Pers Med       Date:  2022-06-21

Review 6.  PharmVar GeneFocus: CYP2B6.

Authors:  Zeruesenay Desta; Ahmed El-Boraie; Li Gong; Andrew A Somogyi; Volker M Lauschke; Collet Dandara; Kathrin Klein; Neil A Miller; Teri E Klein; Rachel F Tyndale; Michelle Whirl-Carrillo; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2021-03-11       Impact factor: 6.903

7.  Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans.

Authors:  Jenna Johnston; Lubbe Wiesner; Peter Smith; Gary Maartens; Catherine Orrell
Journal:  South Afr J HIV Med       Date:  2019-04-29       Impact factor: 2.744

8.  Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana.

Authors:  Monkgomotsi J Maseng; Leabaneng Tawe; Prisca K Thami; Kaelo K Seatla; Sikhulile Moyo; Axel Martinelli; Ishmael Kasvosve; Vladimir Novitsky; Max Essex; Gianluca Russo; Simani Gaseitsiwe; Giacomo M Paganotti
Journal:  Pharmgenomics Pers Med       Date:  2021-03-16

Review 9.  Potential challenges to sustained viral load suppression in the HIV treatment programme in South Africa: a narrative overview.

Authors:  Pascal O Bessong; Nontokozo D Matume; Denis M Tebit
Journal:  AIDS Res Ther       Date:  2021-01-06       Impact factor: 2.250

10.  The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial.

Authors:  Rafael B R León-Cachón; Aileen-Diane Bamford; Irene Meester; Hugo Alberto Barrera-Saldaña; Magdalena Gómez-Silva; María F García Bustos
Journal:  Sci Rep       Date:  2020-06-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.